💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

BRIEF-Valeant Pharmaceuticals CEO responds to Senator McCaskill

Published 2015-10-15, 08:20 a/m
© Reuters.  BRIEF-Valeant Pharmaceuticals CEO responds to Senator McCaskill
HSP
-
BHC
-

Oct 15 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* CEO responds to Sen. McCaskill in a letter dated October 14, 2015
* CEO - Valeant implemented increases in list prices to ensure that prices
reflected value of drugs to hospitals and patients
* CEO -in Q2 2015,reported overall revenue of $4.92 billion; reported revenues
from Nitropress of $126 million, from Isuprel of $121 million
* CEO says "revenues from Nitropress and Isuprel represent a relatively small
portiion of our overall revenue and profitability"
* CEO - co's list price for Nitropress is $880.88/vial,$1472.25/vial for
Isuprel in a 1ml package,$1709.11/vial for 5 ml package
* CEO -"there is a misperception in the media" that co's revenue growth for
existing products has been driven primarily by price
* CEO - average selling price of products co owned was $316.86 for Q3 2015
versus $280.82 for Q3 2014,representing 13 percent increase
* CEO - Nitropress, Isuprel continue to be maufactured by Hospira Inc (N:HSP) under
contracts that existed when they were acquired by co
* CEO - "Valeant has not implemented material changes to Nitropress or Isuprel
since the products were acquired from Marathon"
* CEO-pricing consultant confirms there was room to raise price of Nitropress,Isuprel without depleting funds available to hospitals from payers

* Further company coverage VRX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.